creasing patient need for information regarding treatment and disease knowledge (Tariman, Doorenbos, Schepp, Singhal, & Berry, 2015) , particularly for those who are diagnosed with MM at a younger age (Rood et al., 2015) like S.C. In another study, 19 of 20 older adults newly diagnosed with symptomatic MM wanted to participate in the treatment decision-making process (Tariman, Doorenbos, Schepp, Singhal, & Berry, 2014) . With the growing evidence of patient needs for disease-and treatmentrelated information and patient willingness to participate in cancer treatment decision making (Tariman, Berry, Cochrane, Doorenbos, & Schepp, 2010) , providing patients with relevant and meaningful information on MM treatments can empower them to become active participants in shared treatment decision making (Kane, Halpern, Squiers, Treiman, & McCormack, 2014) .
A Cochrane systematic review of decision aids (DAs) involving 86 studies revealed that the use of DAs can increase patients' participation in making decisions, increase knowledge of available treatment choices, enhance clarity in prioritizing what is important to them, and improve their communication with the healthcare team (Stacey et al., 2014) .
Review Objectives
The objectives of this integrative literature review are to examine all accessible MM treatment DAs for patients and clinicians and to appraise the strength of evidence supporting these DAs using Melnyk and Fineout-Overholt's (2011) Conceptual Framework Knowles's (1984) theory of adult learning guided this review. According to this theory, adults who are diagnosed with cancer will seek treatment information when they are ready and motivated to learn about their cancer treatments. Self-directed learning is the pillar of Knowles's theory. Adults with MM will be intrinsically motivated to learn about their treatment options because of the availability of multiple treatments and because of healthcare consumerism, fueling an increased desire to participate in the treatment decision. The theory of adult learning also posits that adults are more engaged in the learning process when they are learning content that is relevant and practical to their lives; as a result, the integration of patients' personal values and preferences into DAs was also examined.
Methods
To provide a foundation for DAs in MM, the current authors used Whittemore and Knafl's (2005) integrative literature review framework. The current review included peer-reviewed articles, educational pamphlets, and online or web-based myeloma treatment DAs, which were critically appraised for strength of evidence using Melnyk and Fineout-Overholt's (2011) hierarchy of evidence.
Literature Search A literature search was conducted using CINAHL ® Complete, Cochrane, ProQuest Nursing and Allied Health Database, and PubMed. The following relevant Medical Subject Heading (MeSH) and common search terms were used during the search: myeloma, multiple myeloma, decision aid, and decision support techniques. In addition, a Google Scholar search was conducted using the search term treatment decision aid for myeloma. Table 1 illustrates the literature search process with corresponding yields from various computerized databases.
The literature search involved the following inclusion criteria: available fulltext, peer-reviewed articles with a treatment DA component written in English from January 2000 to January 2016. The titles and abstracts were examined, and duplicate articles were excluded from the total. Supportive treatment DAs for MM (e.g., growth factor use, bisphosphonates) were excluded. Twenty-nine articles met inclusion criteria in this review.
Data Synthesis and Analysis
To present the relevant findings in a cohesive manner, the current authors implemented Whittemore and Knafl's (2005) process of data reduction, display, and comparison using a matrix of data; this process helped categorize and summarize the variables of interest in this review. The variables of interest included the intended user of the DAs, format, level of evidence, and consideration of patient values and preferences. Table 2 shows the study DAs, the format of the DAs, the intended audience, and the strength of evidence (level I [lowest quality of evidence] to VII [highest quality of evidence]) for each respective DA based on Melnyk and Fineout-Overholt's (2011) hierarchy of evidence. The categorical data with respective numeric values were then imputed into SPSS ® , version 21.0, for descriptive statistics analysis using frequencies and cumulative percentages (CPs).
Any inconsistencies on assignment of data category according to intended user and hierarchy of evidence were reviewed again by the two reviewers until mutual agreement was reached. Descriptive statistics using frequencies and percentages provided summaries for intended users, the hierarchy of evidence, and the format for all 29 DAs.
Results
Twenty-nine DAs met inclusion criteria and were analyzed and appraised independently by two reviewers. Most DAs (N = 23, CP = 79%) were intended for clinician use only, and all were available electronically. Four DAs (CP = 93%) were developed as an online PDF intended for patients and their caregivers, and 2 DAs (CP = 100%) were intended for clinicians and patients and their caregivers. Further examination of these DAs revealed that they lacked explicit consideration of the patient values and preferences in the treatment decision-making process.
For DAs intended for clinicians, the overall strength of evidence was strong based on Melnyk and Fineout-Overholt's (2011) hierarchy of evidence considering the following results: 12 DAs were systematic reviews of randomized, controlled trials or clinical guidelines developed by MM experts (level I, CP = 41%); 1 DA for clinicians was based on a descriptive study (level VI, CP = 45%); 4 DAs were based on controlled, nonrandomized trials (level III, 55%); 4 DAs were based on systematic reviews of descriptive and qualitative studies (level V, CP = 79%); and 3 DAs were based on case control or cohort studies (level IV, 66%). The 5 DAs intended for patients were based on expert opinion (level VII, CP = 100%), which is the lowest level of evidence. 
Format of Decision Aids
Of the 29 compiled DAs, 17 DAs were available as peer-reviewed journal articles that can be accessed online (CP = 59%); 11 DAs were developed as an online, web-based document (CP = 97%); and only 1 DA was based on a commercially available laboratory genomic profile but could also be accessed online as a treatment decision guide (CP = 100%).
Discussion
This review presents a consolidated evaluation of the available DAs for patients and clinicians related to MM treatment decision making. Most of these DAs are intended for clinician use only. The strength of evidence for the DAs intended for clinicians was strong, with most DAs developed using data from randomized, controlled trials. Only a few DAs were intended for patients and their caregivers and were developed by patient support group organizations, including the International Myeloma Foundation, Multiple Myeloma Research Foundation, Leukemia and Lymphoma Society, and Myeloma Canada. DAs intended for patients had the lowest level of evidence. Further examination of these DAs for patients revealed that they offer general information on myeloma disease processes and the multiple treatment options for MM. However, explicit consideration of patient values and preferences in the decision-making process, which is vital in the implementation of the shared model of cancer care (Kane et al., 2014) , was lacking. A paucity of research shows how these DAs affect overall outcomes related to treatment decisions. Whether these DAs intended for patient use improve patient satisfaction with treatment decisions and decrease decisional regrets is unknown.
Limitations
One of the limitations of this review is the potential bias from the arbitrary creation of criteria for inclusion, which may have unintended selection bias effect. Although multiple computerized databases were used for the literature search, other relevant DAs may have been missed during the selection process.
Implications for Nursing
The identification and categorization of available DAs based on intended users and level of evidence should help oncology nurse clinicians meet the treatment information needs of patients newly diagnosed with MM. Oncology nurses should provide relevant and meaningful treatment information to patients and empower patients to voice their personal preferences for treatment during the shared treatment decision-making process. The information presented in this review could serve as a valuable resource for implementing evidence-based practice in the shared decision-making process for treatment with patients with MM. In addition, the results from this integrative review can serve as a foundation for moving future research toward the development and testing of computerized and individualized treatment DAs in MM that are designed to help patients make informed treatment decisions and improve outcomes. "Decision aids make shared decision making in clinical practice possible, improving patient satisfaction and decreasing decisional regrets."
Conclusion

